Literature DB >> 2147646

The tissue distribution of clodronate (dichloromethylene bisphosphonate) in mice. The effects of vehicle and the route of administration.

J Mönkkönen1, P Ylitalo.   

Abstract

Clodronate (dichloromethylene bisphosphonate) accumulates extensively in bone by binding to hydroxyapatite crystals. In an hypo-osmotic vehicle, it accumulates also in the spleen and, to a lesser extent, in the liver of mice and rats. In the present study, the effects of parenteral routes of administration (intravenous, intraperitoneal, and subcutaneous), drug dose, and injection vehicle on the distribution of [14C]-clodronate were studied in mice. The route of drug injection had no effect on the deposition of clodronate in bone. Either deionized water or iso-osmotic saline used as vehicles for intravenous administration of the drug caused equal and dose-dependent accumulation in bone. In iso-osmotic glucose, however, the osseous deposition of the drug was 2.2-2.5 times lower than in the other vehicles (water, saline, choline chloride). Clodronate accumulated in spleen and liver only after intravenous injection when the drug was in hypo-osmotic vehicle, and the process was saturable at high doses. The hypotonic vehicle probably causes a local hemolysis, and clodronate forms complexes with erythrocyte iron, which is a prerequisite for ingestion of the drug by splenic and hepatic macrophages.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2147646     DOI: 10.1007/BF03190210

Source DB:  PubMed          Journal:  Eur J Drug Metab Pharmacokinet        ISSN: 0378-7966            Impact factor:   2.441


  12 in total

1.  Splenic accumulation of 99mTc-diphosphonate in a patient with sickle cell disease: case report.

Authors:  W Goy; W J Crowe
Journal:  J Nucl Med       Date:  1976-02       Impact factor: 10.057

2.  Letter: Splenic accumulation of 99mTc-diphosphonate.

Authors:  P F Winter
Journal:  J Nucl Med       Date:  1976-09       Impact factor: 10.057

3.  The uptake of clodronate (dichloromethylene bisphosphonate) by macrophages in vivo and in vitro.

Authors:  J Mönkkönen; A Urtti; P Paronen; H A Elo; P Ylitalo
Journal:  Drug Metab Dispos       Date:  1989 Nov-Dec       Impact factor: 3.922

4.  Hemolysis by asbestos.

Authors:  J S Harington; K Miller; G Macnab
Journal:  Environ Res       Date:  1971-04       Impact factor: 6.498

5.  Elimination of phagocytic cells in the spleen after intravenous injection of liposome-encapsulated dichloromethylene diphosphonate. An enzyme-histochemical study.

Authors:  N van Rooijen; R van Nieuwmegen
Journal:  Cell Tissue Res       Date:  1984       Impact factor: 5.249

6.  Metabolism of disodium ethane-1-hydroxy-1,1-diphosphonate (disodium etidronate) in the rat, rabbit, dog and monkey.

Authors:  W R Michael; W R King; J M Wakim
Journal:  Toxicol Appl Pharmacol       Date:  1972-04       Impact factor: 4.219

7.  Toxicity of richterite in hemolysis test and macrophage cultures.

Authors:  Y Collan; V M Kosma; H Anttonen; T Kulju
Journal:  Arch Toxicol Suppl       Date:  1986

8.  Distribution of [14C]clodronate (dichloromethylene bisphosphonate) disodium in mice.

Authors:  J Mönkkönen; P Ylitalo; H A Elo; M M Airaksinen
Journal:  Toxicol Appl Pharmacol       Date:  1987-06-30       Impact factor: 4.219

9.  Effect of etidronate disodium on filterability of sickle cell erythrocytes.

Authors:  B F Van Duzee; R J Sunberg; J J Benedict
Journal:  J Pharm Sci       Date:  1980-05       Impact factor: 3.534

10.  Clodronate kinetics and dynamics.

Authors:  K A Conrad; S M Lee
Journal:  Clin Pharmacol Ther       Date:  1981-07       Impact factor: 6.875

View more
  10 in total

Review 1.  Bisphosphonates. Pharmacology and use in the treatment of tumour-induced hypercalcaemic and metastatic bone disease.

Authors:  H Fleisch
Journal:  Drugs       Date:  1991-12       Impact factor: 9.546

Review 2.  Clodronate: a review of its use in breast cancer.

Authors:  M Hurst; S Noble
Journal:  Drugs Aging       Date:  1999-08       Impact factor: 3.923

3.  Acute inflammatory response to endotoxin in mice and humans.

Authors:  Shannon Copeland; H Shaw Warren; Stephen F Lowry; Steve E Calvano; Daniel Remick
Journal:  Clin Diagn Lab Immunol       Date:  2005-01

4.  The effects of liposome-encapsulated and free clodronate on the growth of macrophage-like cells in vitro: the role of calcium and iron.

Authors:  J Mönkkönen; T D Heath
Journal:  Calcif Tissue Int       Date:  1993-08       Impact factor: 4.333

5.  Clodronate increases the calcium content in fracture callus. An experimental study in rats.

Authors:  M T Nyman; P Paavolainen; T S Lindholm
Journal:  Arch Orthop Trauma Surg       Date:  1993       Impact factor: 3.067

Review 6.  Bone-specific drug delivery systems: approaches via chemical modification of bone-seeking agents.

Authors:  Hideki Hirabayashi; Jiro Fujisaki
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

Review 7.  Bone as an effect compartment : models for uptake and release of drugs.

Authors:  David Stepensky; Lilach Kleinberg; Amnon Hoffman
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

Review 8.  Clodronate. A review of its pharmacological properties and therapeutic efficacy in resorptive bone disease.

Authors:  G L Plosker; K L Goa
Journal:  Drugs       Date:  1994-06       Impact factor: 9.546

Review 9.  Is the Use of Bisphosphonates Putting Horses at Risk? An Osteoclast Perspective.

Authors:  Fernando B Vergara-Hernandez; Brian D Nielsen; Aimee C Colbath
Journal:  Animals (Basel)       Date:  2022-07-03       Impact factor: 3.231

10.  Characterization of the small molecule ARC39, a direct and specific inhibitor of acid sphingomyelinase in vitro.

Authors:  Eyad Naser; Stephanie Kadow; Fabian Schumacher; Zainelabdeen H Mohamed; Christian Kappe; Gabriele Hessler; Barbara Pollmeier; Burkhard Kleuser; Christoph Arenz; Katrin Anne Becker; Erich Gulbins; Alexander Carpinteiro
Journal:  J Lipid Res       Date:  2020-03-10       Impact factor: 5.922

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.